

## Half-yearly report on the liquidity contract with Gilbert Dupont

Market: Euronext Paris  
ISIN code / Mnemo: CH0308403085 / GNRO  
Web site: [www.geneuro.com](http://www.geneuro.com)

Pursuant to the liquidity contract entrusted by GENEURO SA to Gilbert Dupont, as of June 30, 2020, the following assets appeared on the liquidity account:

- Number of shares: 89,381
- Cash balance of the liquidity account: € 87,816.47

During the first half of 2019, the following shares were traded:

|           |               |              |                  |
|-----------|---------------|--------------|------------------|
| PURCHASES | 60,266 shares | € 189,056.24 | 710 transactions |
| SALES     | 55,766 shares | € 179,320.75 | 680 transactions |

As a reminder, as of December 31, 2019, the following resources were booked to the liquidity account:

- Number of shares: 84,881
- Cash balance of the liquidity account: € 97,551.96

### About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 22 employees and rights to 17 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

### Contacts

#### GeNeuro

Jesús Martin-Garcia  
Chairman and CEO  
+41 22 552 4800  
[investors@geneuro.com](mailto:investors@geneuro.com)

#### NewCap (France)

Mathilde Bohin (investors)  
+33 1 44 71 98 52  
Nicolas Merigeau (media)  
+33 1 44 71 94 98  
[geneuro@newcap.eu](mailto:geneuro@newcap.eu)

#### Halsin Partners

Mike Sinclair (media)  
+44 20 7318 2955  
[msinclair@halsin.com](mailto:msinclair@halsin.com)

#### LifeSci Advisors

Chris Maggos (investors)  
+41 79 367 6254  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)